## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Caution: declining volume (38% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($332.42)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 4, Bearish: 2)

**1. Insurer Elevance Targets Out-Of-Network Care With Payment Cuts**
- Source: InkFreeNews.com | 20251226T203621 | Somewhat-Bearish | Relevance: 100%
- Elevance Health, through its subsidiary Anthem Blue Cross and Blue Shield, will implement a 10% reimbursement reduction for out-of-network clinicians at in-network hospitals across 11 states, starting January 1st. This policy aims to address rising costs from out-of-network payment disputes, with exemptions for emergency care and critical access hospitals. While hospitals and physician groups warn of operational disruptions and argue federal protections already exist, Elevance plans to focus enforcement on ongoing patterns to encourage in-network clinician use.

**2. Elevance Health Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251226T163000 | Bullish | Relevance: 100%
- Elevance Health Inc. (ELV) saw its stock rally 1.92% to $349.88, outperforming the broader market which experienced a poor trading session. Both the S&P 500 Index and Dow Jones Industrial Average recorded slight declines. This marks the second consecutive day of gains for Elevance Health.

**3. The past three years for Elevance Health (NYSE:ELV) investors has not been profitable**
- Source: Yahoo Finance UK | 20251227T060801 | Bearish | Relevance: 100%
- The provided content is a cookie consent pop-up from Yahoo and does not contain an actual article about Elevance Health. It outlines Yahoo's use of cookies and user consent options. Therefore, no information about Elevance Health's profitability is available in this text.

**4. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Digimarc, Elevance Health, and Iovance and Encourages Investors to Contact the Firm**
- Source: FOX8 WGHP | 20251226T210810 | Bearish | Relevance: 100%
- Bragar Eagel & Squire, P.C., a shareholder rights law firm, has announced that class action lawsuits have been filed against Krispy Kreme, Digimarc Corporation, Elevance Health, Inc., and Iovance Biotherapeutics, Inc. Investors in these companies are encouraged to contact the firm if they wish to serve as a lead plaintiff in the respective lawsuits. The lawsuits allege that these companies made false and/or misleading statements regarding their business prospects and financial performance, leading to significant stock price declines.

**5. Polianta Ltd Makes New Investment in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251226T130352 | Bullish | Relevance: 100%
- Polianta Ltd has made a new investment in Elevance Health, Inc. (NYSE:ELV) by purchasing 4,500 shares valued at approximately $1.454 million during the third quarter. Elevance Health exceeded Q3 earnings estimates with EPS of $6.03 and revenue of $50.09 billion, representing a 12% year-over-year increase. The company also pays a quarterly dividend of $1.71, and analysts have a "Moderate Buy" rating with an average target price of $396.21.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $78.8B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 13.0 |
| Current P/E | 11.7 |
| YoY Growth | -10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.3% to 1.5% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.98x), long-term trend not supportive. RSI neutral at 58. Volume at 38% of 20MA suggests lack of conviction. OFD pattern: +FTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.47% (CS: 72) | Neutral |
| RSI_14 | 58.5 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 1.023x | Above |
| vs SMA50 | 1.046x | Above |
| vs SMA200 | 0.985x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $349.84
- **Stop Loss:** $332.42 (5.0% risk)
- **Target:** $384.68 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 75
- **Position Value:** $26,238.00
- **Portfolio %:** 26.24%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*